Prediction in Silico of Pathological Response in a Prospective Cohort Study of Early Breast Cancer Patients

Breast cancer (BC) is the most common cancer in women in France with nearly 58,500 new cases and 12,150 deaths estimated in 2018 . Two major achievements have been made in the last five years for breast cancer patients. The first is therapeutic with the approval of immune checkpoint inhibitors in advanced and early triple-negative BC (TNBC) and the impressive efficacy of new antibody-drug conjugated in all BC subtypes. The second is conceptual with the generalization of adaptive therapeutic strategies guided by pathological responses after neoadjuvant therapy in early TNBC, HER2+, HR+ and BRC

Trial Details

NCT ID
NCT05981326
Phase
NA
Sponsor
Institut Cancerologie de l'Ouest
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • Biopsy
  • Blood samples
  • Questionnaires
Locations (sample)
  • Angers, France|47.47156,-0.55202
  • Saint-Herblain, France|47.21154,-1.651

Key Eligibility Criteria

  • Written informed consent obtained from the patient prior to performing any protocol-related procedures, including screening biopsy, blood samples a…
  • 18 years old or at time of written consent
  • Patient with histologically confirmed breast cancer
  • Absence of metastatic disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →